These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 36108903

  • 1. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
    Horino T, Inotani S, Nakajima K, Ohnishi H, Komori M, Terada Y.
    Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
    [No Abstract] [Full Text] [Related]

  • 2. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H, Fumiaki A, Nozomi A, Toshitaka M, Masayoshi Y, Chikako K, Yoshinao M, Tatsuo S, Masahiko K.
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [Abstract] [Full Text] [Related]

  • 3. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 4. Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.
    Wang W, Sun X, Xu Y, Tan W, Liu Y, Zhou J.
    Immun Inflamm Dis; 2024 Jun; 12(6):e1332. PubMed ID: 38934403
    [Abstract] [Full Text] [Related]

  • 5. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, Hara A, Kitazaki T, Kakugawa T, Ishimatsu Y, Satoh M, Mukae H.
    Intern Med; 2019 Mar 15; 58(6):837-841. PubMed ID: 30449789
    [Abstract] [Full Text] [Related]

  • 6. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
    Mehta AA, Paul T, Cb M, Haridas N.
    BMJ Case Rep; 2021 Apr 28; 14(4):. PubMed ID: 33910791
    [Abstract] [Full Text] [Related]

  • 7. [Clinically amyopathic dermatomyositis : a rare entity associated with acute and severe interstitial lung disease].
    Debrus C, Calmes D, Von Frenckell C, Duysinx B, Cataldo D, Corhay JL, Louis R, Guiot J.
    Rev Med Liege; 2023 Jul 28; 78(7-8):441-447. PubMed ID: 37560958
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.
    Yamazoe M, Takeda K, Nagano Y, Nagano K, Kato K, Inoue T, Horiuchi K, Kamada K.
    Intern Med; 2024 Sep 15; 63(18):2571-2578. PubMed ID: 38346740
    [Abstract] [Full Text] [Related]

  • 11. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
    Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A.
    Medicine (Baltimore); 2018 Jun 15; 97(26):e11024. PubMed ID: 29952940
    [Abstract] [Full Text] [Related]

  • 12. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
    Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Ishimatsu Y, Mukae H, Kuwana M, Kohno S, Eguchi K, Aoyagi K, Kawakami A.
    Rheumatology (Oxford); 2012 Jul 15; 51(7):1278-84. PubMed ID: 22378718
    [Abstract] [Full Text] [Related]

  • 13. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis].
    Han YY, Jiang T, Zhang ZH, Li W, Jiang YD, Lu CC, Fei Y, Chen B.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar 15; 54(2):422-425. PubMed ID: 36949709
    [Abstract] [Full Text] [Related]

  • 14. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases.
    Horai Y, Isomoto E, Koga T, Okada A, Kawashiri SY, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Kuwana M, Kawakami A.
    Mod Rheumatol; 2013 Jan 15; 23(1):190-4. PubMed ID: 22460910
    [Abstract] [Full Text] [Related]

  • 15. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.
    Guo L, Zhang X, Pu W, Zhao J, Wang K, Zhang D, Hong S, Ma Y, Wang X, Ye S, Guo Q, Wang J.
    Rheumatology (Oxford); 2023 Jun 01; 62(6):2320-2324. PubMed ID: 36637178
    [Abstract] [Full Text] [Related]

  • 16. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, Lu LJ, Dai M, Lv X, Bao C.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3343-3351. PubMed ID: 33331866
    [Abstract] [Full Text] [Related]

  • 17. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
    Nishioka A, Tsunoda S, Abe T, Yoshikawa T, Takata M, Kitano M, Matsui K, Nakashima R, Hosono Y, Ohmura K, Mimori T, Sano H.
    Mod Rheumatol; 2019 Sep 01; 29(5):814-820. PubMed ID: 30449228
    [Abstract] [Full Text] [Related]

  • 18. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
    Hata K, Kotani T, Matsuda S, Fujiki Y, Suzuka T, Kiboshi T, Wada Y, Shiba H, Shoda T, Kagitani M, Takeuchi T.
    Int J Rheum Dis; 2024 Jan 01; 27(1):e14999. PubMed ID: 38063858
    [Abstract] [Full Text] [Related]

  • 19. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
    Osawa T, Morimoto K, Sasaki Y, Matsuda S, Yamana K, Yano R, Uchiyama T, Goto H.
    Intern Med; 2018 Feb 01; 57(3):387-391. PubMed ID: 29093381
    [Abstract] [Full Text] [Related]

  • 20. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
    Nandy A, Gaïni S, Sore P.
    Scand J Rheumatol; 2018 Jul 01; 47(4):334-335. PubMed ID: 29043891
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.